G1 Therapeutics, Inc.
GTHXNASDAQHealthcare
$7.16
+$0.01(+0.14%)
Market Cap$377748712
P/E Ratio—
52W High$7.19
52W Low$1.08
G1 Therapeutics, Inc. (GTHX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GTHX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $82.51M | $51.30M | $31.48M | $45.28M | $0.00M |
| Cost of Revenue | $7.20M | $3.75M | $2.02M | $0.00M | $0.36M |
| Gross Profit | $75.32M | $47.55M | $29.46M | $45.28M | ($0.36M) |
| Gross Margin %(computed) | 91.28% | 92.69% | 93.60% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $43.71M | $83.32M | $76.22M | $73.27M | $89.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $68.49M | $40.04M |
| Total Operating Expenses | $114.84M | $183.73M | $171.92M | $141.76M | $129.04M |
| Operating Income | ($39.53M) | ($136.18M) | ($142.46M) | ($96.48M) | ($129.04M) |
| Operating Margin %(computed) | -47.91% | -265.45% | -452.59% | -213.04% | — |
| Interest Income | $2.47M | $0.75M | $0.04M | $0.95M | $6.59M |
| Interest Expense | $10.04M | $10.43M | $4.67M | $1.78M | $0.00M |
| Income Before Tax | ($44.85M) | ($145.86M) | ($147.43M) | ($97.84M) | ($122.45M) |
| Income Tax Expense | $3.12M | $1.70M | $0.93M | $1.41M | ($0.36M) |
| Net Income | ($47.97M) | ($147.56M) | ($148.35M) | ($99.25M) | ($122.09M) |
| Net Margin %(computed) | -58.13% | -287.63% | -471.32% | -219.18% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.93 | $-3.38 | $-3.54 | $-2.62 | $-3.26 |
| Wtd Avg Shares | 51.73M | 43.63M | 41.94M | 37.88M | 37.50M |
| EBITDA | ($34.30M) | ($134.90M) | ($142.46M) | ($95.48M) | $0.00M |
| EBITDA Margin %(computed) | -41.57% | -262.95% | -452.59% | -210.85% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more G1 Therapeutics, Inc. data
About G1 Therapeutics, Inc. (GTHX) Income Statement
G1 Therapeutics, Inc. (GTHX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, GTHX reported revenue of $0.08B, gross profit of $0.08B (gross margin 91.28%), and net income of ($0.05B) — a net profit margin of -58.13%.
Frequently asked questions
GTHX · 4 questionsG1 Therapeutics, Inc. (GTHX) reported revenue of $0.08B for 2023, up 60.8% year-over-year.
GTHX revenueGTHX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09